ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access

Abhi Bhadra, Shweta Singh, Shaswat Chandrakar, Vanshika Kumar, Sakshi Sankhla, Sayuj Raj T. and E. Selvarajan

Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur – 603 203, Tamil Nadu, India.
J Pure Appl Microbiol. 2020;14(suppl 1):979-988 | Article Number: 6348
Received: 08/05/2020 | Accepted: 21/05/2020 | Published: 28/05/2020

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global epidemic status claiming more than 319K lives and affecting more than 4.81M people and counting worldwide. Considering the severity of the situation and low recovery rate many research institutions and pharmaceutical industries are rushing to learn more about this new virus and the morbid physiology of this disease with effective diagnostic methods, therapeutic agents and vaccines. Various approaches are highlighted for comparing the possible treatment methods available for COVID-19 some of which are BCG vaccination on COVID-19 and Non-pharmaceutical interventions, drug based clinical trials of Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, ChAdOx1 nCoV-19, Remdesivir, Stem Cell therapy and mesenchymal stromal cell therapy, etc.


Lopinavir, Ritonavir, Chloroquine, Hydroxychloroquine, Stem Cell Therapy, Cytokines, Remdesivir

Article Metrics

Article View: 638

Share This Article

© The Author(s) 2020. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.